1. Mbatani M, Olawaiye AB, Prat J. Uterine sarcomas. Int J Gynecol Obstet 2018; 114 (Suppl 2): 51–58. doi: 10.1002/ijgo.12613.
2. Oliva E. Cellular mesenchymal tumors of the uterus: a review emphasizing recent observations. Int J Gynecol Pathol 2014; 33 (4): 374–384. doi: 10.1097/PGP.0000000000000141.
3. Diagnosticko-léčebné protokoly MOÚ – gynekologické nádory. 2024 [online]. Dostupné z: https: //static.mou.cz/d/mou.cz/files/4373.pdf/s-baa20ffabc92?_ts=1715082385.
4. Špaček J, Laco J, Petera J et al. Prognostické faktory u mezenchymálních a smíšených nádorů děložního těla. Ceska Gynekol 2009; 74 (4): 292–297.
5. Giuntoli RL 2nd, Metzinger DS, DiMarco CS et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 2003; 89 (3): 460–469. doi: 10.1016/s0090-8258 (03) 00137-9.
6. Koivisto-Korander R, Butzow R, Koivisto AM et al. Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990–2001. Gynecol Oncol 2008; 111 (1): 74–81. doi: 10.1016/j.ygyno.2008.06.002.
7. Mayerhofer K, Obermair A, Windbichler G et al. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol 1999; 74 (2): 196–201. doi: 10.1006/gyno.1999.5436.
8. Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer 2008; 112 (4): 820–830. doi: 10.1002/cncr. 23245.
9. D‘Angelo E, Espinosa I, Ali R et al. Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis. Gynecol Oncol 2011; 121 (2): 328–333. doi: 10.1016/j.ygyno.2011. 01.022.
10. Chan JK, Kawar NM, Shin JY et al. Endometrial stromal sarcoma: a population-based analysis. Br J Cancer 2008; 99 (8): 1210-1215. doi: 10.1038/sj.bjc.6604527.
11. Lee CH, Mariño-Enriquez A, Ou W et al. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol 2012; 36 (5): 641–653. doi: 10.1097/PAS.0b013e31824a7b1a.
12. Tanner EJ, Garg K, Leitao MM Jr et al. High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes. Gynecol Oncol 2012; 127 (1): 27–31. doi: 10.1016/ j.ygyno.2012.06.030.
13. Li JY, Mutlu L, Tymon-Rosario J et al. Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sites. Gynecol Oncol Rep 2021; 39: 100913. doi: 10.1016/j.gore.2021.100913.
14. Ghartimagar D, Shrestha B, Ghosh A et al. Adenosarcoma of uterus – rare biphasic malignant tumor: a case report. JNMA J Nepal Med Assoc 2021; 59 (234): 200–203. doi: 10.31729/ jnma.5373.
15.Wang Q, Sun S, Cai J et al. Uterine adenosarcoma: a case report and review of the literature. Am J Nucl Med Mol Imaging 2023; 13 (2): 70–76.
16. Hasegawa C, Washimi K, Hiroshima Y et al. Differential diagnosis of uterine adenosarcoma: identification of JAZF1-BCORL1 rearrangement by comprehensive cancer genomic profiling. Diagn Pathol 2023; 18 (1): 5. doi: 10.1186/s13000-022-01279-4.
17. Doporučené postupy ČGPS ČLS JEP – Sledování pacientek po léčbě prekanceróz a zhoubných nádorů ženských pohlavních orgánů. 2019 [online]. Dostupné z: https: //cgps.cz/doporucene-postupy/onkogynekologie/ o-2019-07-sledovani-pacientek-po-lecbe-prekanceroz-a-zn-zenskych-pohlavnich-organu/ ?layout=default.
18. Hořínová V, Drábová K, Nosková H e tal. Syndrom DICER1. Klin Onkol 2019; 32 (Suppl 2): 123–127. doi: 10.14735/amko2019S123.
19. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice. 2024 [online]. Dostupné z: https: //www.svod.cz/.
20. Zizolfi B, Foreste V, Di Spiezio Sardo A et al. Fertility sparing management of uterine adenosarcoma: case report and literature review. Facts Views Vis Obgyn 2021; 12 (4): 315–318.
21. Goh C, Lin XH, Chin PS et al. Uterine preservation in a young patient with adenosarcoma of the uterus – case report and review of literature. Gynecol Oncol Rep 2018; 25: 27–29. doi: 10.1016/j.gore.2018.05.002.
22. Wang Q, Sun S, Cai J et al, Uterine adenosarcoma: a case report and review of the literature. Am J Nucl Med Mol Imaging 2023; 13 (2): 70–76.
23. de Vries M, Perquin DA. Non-puerperal uterine inversion due to submucous myoma in a young woman: a case report. J Med Case Rep 2010; 4: 21. doi: 10.1186/1752-1947-4-21.
24. Mužná L, Pilka R. Inverze dělohy. Ceska Gynekol 2017; 82 (2): 139–144.
25. Leconte I, Cecile T, Bongiorno A et al. Non--puerperal uterine inversion. J Belg Soc Radiol 2016; 100 (1): 47. doi: 10.5334/jbr-btr.974.
ORCID autorů
L. Klenovská 0009-0003-2297-9627
I. Meixnerová 0000-0002-4837-4795
L. Minář 0000-0001-9088-5428
Doručeno/Submitted: 4. 12. 2024
Přijato/Accepted: 12. 12. 2024
doc. MUDr. Luboš Minář, Ph.D.
Gynekologicko-porodnická klinika
LF MU a FN Brno
Obilní trh 526/11
602 00 Brno